Lancet respir med:全血基因特征用于结核病的预测

2020-01-19 MedSci MedSci原创

研究发现,多数血液转录生物标志物仅能反应3-6个月的结核病风险,尚缺少满足WHO2年预测能力的生物标志物

目前,已有多个活动性和早期结核病的血液转录标志物指征,近日研究人员就潜在早期结合病特征的特异性和敏感性进行了比较。

研究人员搜索Medline和Embase发现的候选全血mRNA特征,主要目的是诊断活动性或早期结核病,与健康或有潜伏性结核病感染的对照组相比。研究人员在全血转录组数据中测试合格特征的性能,包括培养证实和临床或放射诊断的肺结核或肺外结核病例。

研究人员筛选出17个候选mRNA特征,数据集包括来自南非、埃塞俄比亚、冈比亚和英国127例初发结核病病例的183个样本。8个主要反映干扰素和肿瘤坏死因子诱导基因表达的特征,对2年内的初次结核病发病具有同等的诊断准确率,ROCAUC为 0.70-0.77。所有8个特征的敏感性随着无病时间间隔的增加而下降。以高于未感染对照组平均值的两个SD为限,8个特征在24个月内阳性预测敏感性为24.7-39.9%,在3个月内达到47.1-81.0%,相应的特异性超过90%。

研究发现,多数血液转录生物标志物仅能反应3-6个月的结核病风险,尚缺少满足WHO2年预测能力的生物标志物。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830422, encodeId=d8301830422c1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 26 02:31:00 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992468, encodeId=b596199246825, content=<a href='/topic/show?id=f51241e935c' target=_blank style='color:#2F92EE;'>#基因特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41793, encryptionId=f51241e935c, topicName=基因特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jul 24 15:31:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254322, encodeId=1aa01254322c1, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610197, encodeId=f1bc161019e65, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-12-26 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830422, encodeId=d8301830422c1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 26 02:31:00 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992468, encodeId=b596199246825, content=<a href='/topic/show?id=f51241e935c' target=_blank style='color:#2F92EE;'>#基因特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41793, encryptionId=f51241e935c, topicName=基因特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jul 24 15:31:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254322, encodeId=1aa01254322c1, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610197, encodeId=f1bc161019e65, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830422, encodeId=d8301830422c1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 26 02:31:00 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992468, encodeId=b596199246825, content=<a href='/topic/show?id=f51241e935c' target=_blank style='color:#2F92EE;'>#基因特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41793, encryptionId=f51241e935c, topicName=基因特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jul 24 15:31:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254322, encodeId=1aa01254322c1, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610197, encodeId=f1bc161019e65, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830422, encodeId=d8301830422c1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 26 02:31:00 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992468, encodeId=b596199246825, content=<a href='/topic/show?id=f51241e935c' target=_blank style='color:#2F92EE;'>#基因特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41793, encryptionId=f51241e935c, topicName=基因特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Fri Jul 24 15:31:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254322, encodeId=1aa01254322c1, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610197, encodeId=f1bc161019e65, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Jan 21 09:31:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]

相关资讯

到2050年,抗生素耐药性每年可导致1000万人死亡

据经济学人智库报告显示,全世界对于应对日益严重的耐药结核病威胁尚未做好准备,有四分之三患有空气传染病的人未被诊断和治疗。成千上万的未经诊断和未经治疗的耐药结核病需要采取"紧急行动"。

Nature:结核菌致病有 “元凶”

近日,同济大学医学院、同济大学附属上海市肺科医院教授戈宝学团队联合上海科技大学饶子和院士团队研究发现,结核菌中有一种蛋白非常 “聪明”,它能利用人体的蛋白分子攻击自身免疫系统,从而导致结核病发生。相关成果 1 月 16 日在线发表于《自然》。

遏制结核病,听听专家怎么说

世界卫生组织提出,到2035年,终止结核病流行,届时要将结核病患病率降到10/10万以下;国家卫生健康委刚刚发布的《遏制结核病行动计划(2019~2022年)》,则在《全国十三五结核病防治规划》基础上提出了具体任务。这些目标和计划的出台,为今后结防工作指出了新方向,我国结核病防治工作也迈入了新时代。日前,由中华医学会结核病学分会等主办的2019年全国结核病学术大会上,多位专家围绕上述主题作了分享。

2019 NTAC/CDC建议:结核病的筛查、检测和治疗

2019年5月,美国国家结核病控制协会(NTAC)联合美国疾病控制与预防中心(CDC)发布了结核病的筛查、检测和治疗建议。本文基于2005年CDC预防结核杆菌感染传播指南进行更新,主要内容涉及基线结核病的筛查和检测,以及治疗等。

结核病耐药后无药可用?人工智能帮患者走出“至暗时刻”

在许多人印象中,结核病不过是一种过时的“白色瘟疫”。然而,“狡猾”的结核病并未被人类打败。